Synapse - Dana Rathkopf

Results (18)

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): A randomised, placebo-controlled, double-blind, multinational, phase 3 study

Journal Article

Saad, F.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F.; Goodman, O. B. Jr; Oudard, S.; Steuber, T.; Suzuki, H.; Wu, D.; more...
Lancet Oncology (2021)

Fulltext@MSK | Save

Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Saad, F.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F.; Goodman, O.; Oudard, S.; Steuber, T.; Suzuki, H.; Pieczonka, C. M.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT)

Meeting Abstract

De Bono, J. S.; Cook, N.; Yu, E. Y.; Lara, P. N.; Wang, J. S.; Yamasaki, Y.; Yamamiya, I.; Gao, P.; Calleja, E. M.; Rathkopf, D. E.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA plus P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)

Meeting Abstract

McBride, S. M.; Spratt, D. E.; Kollmeier, M.; Abida, W.; Xiao, H.; Slovin, S. F.; Paller, C. J.; Deville, C.; Den, R. B.; Hearn, J. W. D.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy

Journal Article

Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
European Urology Open Science (2021)

Fulltext@MSK | Save

SAABR: Single arm phase II study of abiraterone + atezolizumab + GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)

Meeting Abstract

Rathkopf, D. E.; Decker, B.; Schum, P.; McBride, S.
Annals of Oncology (2021)

Fulltext@MSK | Save

A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)